KFAR-SABA, Israel–(BUSINESS WIRE)–CathWorks announced the approval of a new CPT code 0523T for
non-invasive, 3D FFRangio™ enabled interpretation of possible
atherosclerotic stenosis during coronary angiography interventions. The
code issuance is a major step forward in helping physicians objectively
and cost-effectively determine if PCI (percutaneous coronary
intervention) is indicated and revascularization has occurred in every
coronary angiography procedure.

This breakthrough in objective intraprocedural decision-making, is made
possible by the development of the CathWorks FFRangio™ System. It is the
non-invasive FFR platform that quickly and precisely delivers objective
multi-vessel physiologic measurements to cost-effectively optimize and
confirm intraprocedural PCI therapy decisions.

CPT code 0523T enables healthcare providers using the CathWorks
FFRangio™ System to be reimbursed for:

Intraprocedural coronary fractional flow reserve (FFR) with 3D
functional mapping of color-coded FFR values for the entire coronary
tree, derived from coronary angiogram data that allow real-time review
and interpretation of possible atherosclerotic stenosis(es) intervention.

CathWorks CEO Jim Corbett said, “CPT code 0523T approval is a very
important step for our company and the market. The CPT code decision
also reflects the long-term clinical importance of objective FFR-based
PCI decision-making. Creating a long-term reimbursement solution to
support intraprocedural FFRangio™ will enable physicians, patients, and
payers to realize the proven clinical and economic benefits of FFR on an
every-case basis.”

The CathWorks FFRangio™ System is in development and is not yet FDA

About CathWorks

CathWorks is a medical technology company focused on applying its
advanced computational science platform to optimize PCI therapy
decisions and elevate coronary angiography from visual assessment to an
objective FFR-based decision-making tool for physicians. FFR-guided PCI
decision-making is proven to provide significant clinical benefits for
patients with coronary artery disease and economic benefits for patients
and payers. The company’s focus today is specifically on bringing the
CathWorks FFRangio™ System to market to provide quick, precise, and
objective intraprocedural FFR guidance that is practical for every case.


Source link